CA-125 ELIMination rate constant K (KELIM) Is A Marker Of Chemosensitivity In Patients With Ovarian Cancer: Results from the Phase II CHIVA trial.
Fiche publication
Date publication
mars 2020
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr KURTZ Jean-Emmanuel
Tous les auteurs :
You B, Robelin P, Tod M, Louvet C, Lotz JP, Abadie-Lacourtoisie S, Fabbro M, Desauw C, Bonichon-Lamichhane N, Kurtz JE, Follana P, Leheurteur M, Del Piano F, Ferron G, DE Rauglaudre G, Ray-Coquard I, Combe P, Chevalier Place A, Joly F, Leary A, Pujade-Lauraine E, Freyer G, Colomban O
Lien Pubmed
Résumé
In ovarian cancer patients receiving neoadjuvant chemotherapy, the first line treatment success will depend on both the tumor primary chemosensitivity and the completeness of interval debulking surgery (IDS). The modeled CA-125 ELIMination rate constant K (KELIM), calculated with the CA-125 longitudinal kinetics during the first 100 chemotherapy days, is a validated early marker of tumor chemosensitivity. The objective was to investigate the role of the chemosensitivity relative to the success of first line medical-surgical treatment.
Référence
Clin. Cancer Res.. 2020 Mar 24;: